Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0EQRAF
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-CXCR4 ADC 713
|
|||||
| Synonyms |
Anti-CXCR4-ADC-713
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 5 Indication(s)
Acute lymphocytic leukemia [ICD11:2B33]
Investigative
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Multiple myeloma [ICD11:2A83]
Investigative
Non Hodgkin lymphoma [ICD11:2B33]
Investigative
Non-small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
4
|
|||||
| Antibody Name |
Anti-CXCR4 mAb h17-NV.TS
|
Antibody Info | ||||
| Antigen Name |
C-X-C chemokine receptor type 4 (CXCR4)
|
Antigen Info | ||||
| Payload Name |
Aur0131
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
AmPEG6C2
|
Linker Info | ||||
| Conjugate Type |
Random conjugation conjugation through nucleophilic lysines.
|
|||||
| Combination Type |
AmPEG6C2-Aur0131
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Patient-derived Xenograft Model
| Standard Type | Value | Units | Animal Model (No. of PDX) |
|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
≈ 50.6
|
%
|
Non-small cell lung cancer PDX model (PDX: TM00226)
|
Revealed Based on the Cell Line Data
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Half Maximal Inhibitory Concentration (IC50) |
39.7
|
nM
|
Jurkat cells
|
T acute lymphoblastic leukemia
|
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 50.60% (Day117) | Positive CXCR4 expression (CXCR4+++/++) | ||
| Method Description |
In vivo anti-tumour activity of ADC 713 in the patient-derived xenograft TM00226 as monotherapy or in combination with gemcitabine chemotherapy, N=5 mice/group.
|
||||
| In Vivo Model | Non-small cell lung cancer PDX model (PDX: TM00226) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 39.70 nM | High CXCR4 expression (CXCR4+++) | ||
| Method Description |
Cells were seeded in a culture-treated 96-well clear plate and incubated at 37°C under 5% CO2 for 24h. Serially diluted samples (50L) were added to each well and the plate was incubated at 37°C for 72h.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.